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Abstract
 .  .Transcription factors nuclear factor-k B NF-k B and activator protein-1 AP-1 play an important role in the induction
of pro-inflammatory factors such as cytokines and cell adhesion molecules, which could be involved in the pathogenesis of
glomerulonephritis. We have recently reported the pathogenic significance of NF-k B activation in experimental glomerulo-
nephritis in rats. In this study, we investigated the pathogenic relevance of AP-1 activation in nephrotoxic serum
 .NTS -induced glomerulonephritis. Increased AP-1 DNA-binding activity was detected in nephritic glomeruli by a gel shift
assay. The kinetics of AP-1 activation was similar to that of NF-k B. Activation of both NF-k B and AP-1 preceded
proteinuria, an important pathophysiological parameter for glomerulonephritis. Treatment with prednisolone, a glucocorti-
coid hormone, prevented activation of both NF-k B and AP-1 in glomeruli and subsequent mRNA expression of NF-k B-
and AP-1-regulated genes. Prednisolone was also effective therapeutically and reduced DNA-binding activities of NF-k B
and AP-1 which are already activated in nephritic glomeruli. These results suggest that activated NF-k B and AP-1 may play
an important pathogenic role in glomerulonephritis and the anti-nephritic action of glucocorticoids may be mediated through
the suppression of these transcription factors. q 1997 Elsevier Science B.V.
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1. Introduction
Pathophysiological studies of glomerulonephritis
have demonstrated the pathogenic significance of
w xpro-inflammatory factors such as cytokines 1–5 ,
w x w xcell adhesion molecules 6–8 , growth factors 9–12 ,
w xextracellular matrix components 13 and matrix met-
w xalloproteinases 14 . These pro-inflammatory factors
) Corresponding author. Fax.: q81 6 300 2593; E-mail:
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induce proliferation of renal mesangial cells and ma-
w xtrix accumulation in nephritic glomeruli 15,16
which, as a consequence, can lead to renal insuffi-
ciency.
Studies examining the gene regulation of these
pro-inflammatory factors in nephritic glomeruli are
important for the understanding of the pathogenic
mechanisms of glomerulonephritis. Promoter analy-
ses, using cultured cells, have shown that the expres-
sion of most of these pro-inflammatory factors is
transcriptionally regulated. Since several transcription
0925-4439r97r$19.00 q 1997 Elsevier Science B.V. All rights reserved.
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factors, especially NF-k B and AP-1, could play piv-
w xotal roles in their gene expression 17–30 , attention
has been focused on the regulation and function of
transcription factors in inflammatory lesions. Re-
cently, we reported the in vivo activation of NF-k B
 .in nephritic glomeruli of nephrotoxic serum NTS -
w xinjected rats 31 . We demonstrated that pyrrolidine
dithiocarbamate, a potent inhibitor of NF-k B, sup-
pressed both NF-k B activation and development of
w xglomerulonephritis 31 . However, there is not enough
information on the pathogenic role of transcription
factors in glomerulonephritis.
Glucocorticoids are widely used for the treatment
of human chronic inflammatory diseases including
glomerulonephritis. Glucocorticoids are also effective
in experimental animal models of inflammatory dis-
eases. Possible mechanisms of their anti-inflamma-
tory effects include the inhibition of gene expression
of several pro-inflammatory factors such as cytokines
w xand cell adhesion molecules 32,33 . In vitro studies
have suggested that the repression of NF-k B- and
AP-1-dependent transcription is a major component
of the glucocorticoid-mediated inhibition of gene ex-
w xpression 34–38 . However, the precise molecular
mechanisms of the therapeutic effects of glucocorti-
coids on human and experimental inflammatory dis-
eases are not yet fully understood.
In this study, we investigated the pathophysiologi-
cal significance of AP-1 activation and the effects of
glucocorticoid on the activation of NF-k B and AP-1,
using a rat NTS-nephritis model. We found that AP-1
was activated in nephritic glomeruli with similar
kinetics to NF-k B activation and that glucocorticoid
suppressed the activation of NF-k B and AP-1 in
parallel with the suppression of glomerulonephritis.
2. Materials and methods
2.1. Induction of glomerulonephritis
Rabbit anti-glomerular basement membrane
 .  .GBM antisera nephrotoxic sera; NTS were pre-
w xpared by the procedure described previously 31 . In
brief, rabbits were immunized subcutaneously with
 .GBM of WKY rats Charles River Japan . After three
boosters, sera were prepared and heat-decomple-
mented. The specificity of NTS was confirmed by
immunofluorescence on the frozen sections of kidney
 .using fluorescein isothiocyanate FITC conjugated
 .anti-rabbit IgG Jackson . Immunofluorescence was
strongly detected along the GBM in rats injected with
NTS. Glomerulonephritis was induced in male WKY
 .rats 180–280 g body weight by intravenous injec-
tion through a tail vein of 0.5 ml of NTS diluted
.eighty-fold with PBS per 200 g body weight of rats.
2.2. Preparation of glomerular nuclear extracts
At the indicated time after NTS injection, kidneys
were perfused with saline under ether anesthesia to
eliminate circulating blood cells. Renal cortex from
one animal was minced in small pieces and glomeruli
were isolated by a fractional sieving technique. In
brief, the cortex was first sieved using a mesh with a
pore size 355mm. The sieved cortex was collected
with 20 ml PBS and passed through a second mesh
with a pore size 125mm. The fraction from this mesh
was further sieved using a 75mm mesh. Glomeruli
trapped on the final mesh were collected with PBS
and centrifuged at 2000=g for 10 min at 48C.
The procedure used for the preparation of nuclear
extracts from isolated glomeruli was described previ-
w xously 31 with slight modifications. In brief,
glomeruli were suspended in 500 ml of buffer A
w  .10 mM HEPES pH 7.9 , 10 mM KCl, 0.1 mM
 .EDTA, 0.1 mM EGTA, 1 mM dithiothreitol DTT ,
 .and 0.5 mM phenylmethylsulfonyl fluoride PMSF ,
x10 mgrml aprotinin, 10 mgrml leupeptin and lysed
by homogenization in a Dounce homogenizer of B-
type pestle with 50 strokes. The homogenates were
chilled on ice for 15 min. 30 ml of 10% Nonidet P-40
was added and samples were vortexed vigorously for
10 s. The nuclear fraction was precipitated by cen-
trifugation at 15 000=g for 5 min at 48C and sus-
wpended in 50–100 ml of buffer B 20 mM HEPES
 .pH 7.9 , 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, and 1 mM PMSF, 10 mgrml aprotinin,
x10 mgrml leupeptin . The mixture was left on ice for
15 min with frequent agitation. Nuclear extracts were
prepared by centrifugation at 15 000=g for 5 min at
48C and stored at y808C. Protein concentration was
determined by the DC protein assay reagent Bio-
.Rad .
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2.3. Gel shift assay
Gel shift assay was performed as described previ-
w xously 31 . Sequences of oligonucleotides for DNA
probes were as follows: AP-1, 5X-GATTCGT-
GACTCAGCACAGG-3X; Octamer binding protein
 . X XOct , 5 -GATTCGATTTGCATGCACAG-3 ; NF-
k B, 5X-GTTCGACAGAGGGGACTTTCCGAGAG-
GCAAC-3X. Where indicated, the DNA binding reac-
tion was performed in the presence of non-radio-
labeled oligonucleotide competitors.
2.4. Pharmacological study of glucocorticoid
A synthetic glucocorticoid, prednisolone Nacalai
.tesque , suspended in H O was administered orally,2
once a day, 30 min before NTS injection at a dose of
2 mgrkg. Rats were administered 1 ml of the sus-
 .pended prednisolone 0.4 mgrml per 200 g body
weight. Control animals received the same volume of
H O. Urine samples were collected for 24 h on days2
3 and 8 by keeping each animal in an individual
metabolic cage. Urinary protein concentration was
determined by protein assay reagent using bovine
 .serum albumin as a standard Bio-Rad . When thera-
peutic effects were investigated, daily treatment with
prednisolone was started on the third day and urinary
protein excretion was determined on days 0, 3, 5 and
7.
2.5. Effects of glucocorticoid on NF-kB and AP-1
acti˝ation
Glomerular nuclear extracts were prepared from
isolated glomeruli of one rat and gel shift assays for
NF-k B and AP-1 were carried out according to the
procedure described above. When therapeutic effects
were investigated, treatment with prednisolone
 .2 mgrkg was started on day 3 and nuclear extracts
were prepared 2 days after prednisolone treatment.
2.6. Northern blot analysis
Total RNA was isolated from glomeruli of two rats
 .by using Isogen Nippon gene . 15mg of total RNA
was electrophoresed in a 1% agarose–formaldehyde
gel and transferred onto a Hybond–Nqnylon filter
 .Amersham . The filter was hybridized with cDNA
probes. cDNA fragments for murine interleukin-1b
 . IL-1b , monocyte chemoattractant protein-1 MCP-
.  .1 , rat intercellular adhesion molecule-1 ICAM-1 ,
 .murine transforming growth factor-b1 TGF-b1 and
rat glyceraldehyde-3-phosphate dehydrogenase
 . w 32 xGAPDH were labeled with a- P dCTP
 .3000 Cirmmol, Amersham by DNA labeling kit
 .with random primers TaKaRa .
2.7. Immunohistochemistry
Kidney was immediately frozen in powdered dry
 .ice. Cryostat sections 7mm were mounted onto
 .APS coated slides Matsunami and stored at y808C.
The sections were thawed and the tissues were fixed
in buffered 2% paraformaldehyde, 0.2% glutaralde-
hyde and 0.02% NP-40 for 5 min. To inactivate the
endogenous peroxidase, the sections were treated with
0.3% hydrogen peroxide in methanol for 30 min.
Nonspecific binding was blocked with normal horse
 .serum Vector . The sections were incubated with
 .biotinylated anti-rabbit IgG Vector at room temper-
ature for 2 h. After washes with PBS for three times,
the sections were incubated with streptavidin biotin
 .peroxidase complex Vector , washed again, and in-
X  .cubated in 0.02% 3,3 -diaminobenzidine Wako with
0.006% hydrogen peroxide. The sections were counter
stained with hematoxylin.
( )2.8. Enzyme-linked immunosorbent assay ELISA
Anti-rabbit IgG level in the rat serum was deter-
mined by ELISA. 100 ml of 10 mgrml normal rabbit
 .IgG ICN was coated on a 96-well plate at 48C
overnight. After blocking, 100 ml of test sera, diluted
twenty-fold with PBS, was added to each well and
incubated at room temperature for 2 h. The wells
were washed and incubated with horseradish peroxi-
 .dase-conjugated goat anti-rat IgG Jackson . The per-
oxidase activity was measured using 2,2X-azino-
 .  .bis 3-ethyl-benzothazoline-6-sulfonic acid Wako as
a substrate and V value of the reaction was calcu-max
lated.
3. Results
3.1. Kinetics of proteinuria
Proteinuria was measured as a parameter for the
development of glomerulonephritis. Urinary protein
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Fig. 1. Proteinuria in NTS-nephritis in WKY rats. Urine samples
were collected for 24 h on day 0, 1, 3, 5, 7, 10 and 14 from
 .  .normal I and NTS-treated B rats. Data are mean"S.E. of
)) five rats. P-0.01 compared to the normal control Student’s
.t-test .
excretion for 24 h from day 1 was at a normal level
 .Fig. 1 . All animals showed significant proteinuria
 .on day 3 and thereafter Fig. 1 . Proteinuria and other
parameters such as blood urea nitrogen and serum
cholesterol level gradually increased at least to 6
 .weeks data not shown . Finally, rats showed chronic
w xrenal failure with glomeruloscrelosis 39 . Herein,
pathophysiological analysis was further conducted on
 .an earlier stage from the onset to day 14 , where
inflammatory reaction is actively on-going.
3.2. AP-1 DNA-binding acti˝ity in nephritic glomeruli
In the previous study, we monitored the DNA-bi-
nding activity of transcription factors in isolated
w xglomeruli by gel shift assays 31 . Using this system,
we determined AP-1 DNA-binding activity in the
nuclear extracts of glomeruli isolated from NTS-
  ..treated rats Fig. 2 A . AP-1 DNA-binding activity
 .  .Fig. 2. Kinetic analysis of AP-1 and Oct DNA-binding activities in nephritic glomeruli treated with NTS. AP-1 A and Oct B
 .DNA-binding activities were determined by the gel shift assays with nuclear extracts 5mg of protein prepared from isolated normal
 .  .  .  .  .glomeruli lanes 1 and 8 and nephritic glomeruli on days 1 lanes 2 and 9 , 3 lanes 3 and 10 , 5 lanes 4 and 11 , 7 lanes 5 and 12 , 10
 .  .lanes 6 and 13 and 14 lanes 7 and 14 . One specific band for AP-1 and two specific bands for Oct are indicated as AP-1, Oct-1 and
Oct-2, respectively. The lower arrow head, F, indicates free probes. One animal was used on each day and similar results were obtained in
another experiment.
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  .in normal glomeruli was at a low level Fig. 2 A ,
.lane 1 . In contrast, increased AP-1 DNA-binding
activity was detected in the glomeruli of NTS-treated
  . .rats Fig. 2 A , lanes 2–7 . Kinetic analysis indicated
that significant AP-1 activation was detected on day
  . .1 after NTS injection Fig. 2 A , lane 2 and the
activation was sustained, at least, to day 14 Fig.
 . .2 A , lane 7 . On days 3, 5, and 14, activation was at
  . .the highest level Fig. 2 A , lanes 3, 4 and 7 . The
kinetics of AP-1 activation was similar to that of
w xNF-k B activation 31 . Activation of both NF-k B
 .and AP-1 preceded proteinuria Fig. 1 . These results
indicate that both NF-k B and AP-1 are activated in
nephritic glomeruli during the development of
glomerulonephritis.
To evaluate the specificity of NF-k B and AP-1
activation, we also monitored DNA-binding activities
of ubiquitously expressed Octamer binding proteins
 .Oct using the same nuclear extracts as the AP-1
  ..assay Fig. 2 B . Two specific bands were detected
by gel shift assay. Intensity of the slower migrating
band, an Oct-1 like protein, was not changed during
  . .the experiment Fig. 2 B , lanes 8–14 . In contrast,
the faster migrating band, an Oct-2 like protein, was
  .only detected in nephritic glomeruli Fig. 2 B , lanes
.9–14 . These results indicate that some transcription
factors are selectively activated in nephritic glomeruli.
A competition gel shift assay was performed to
determine the specific AP-1 DNA-binding activity
 .Fig. 3 . The AP-1 DNA-binding activity was com-
peted out by a non-radiolabeled oligonucleotide con-
 .taining an AP-1 binding site Fig. 3, lane 2 . How-
ever, AP-1 binding activity was not affected by an
 .Oct binding site Fig. 3, lane 3 , indicating specific
DNA-binding of the AP-1 protein.
3.3. Effect of glucocorticoid on glomerulonephritis
We determined the effect of prednisolone, a syn-
thetic glucocorticoid used for the treatment of
glomerulonephritis, on NTS-nephritis. Urinary pro-
tein excretion on days 3 and 8 was suppressed by
 .prednisolone at 2 mgrkg Fig. 4 . Other serum and
urine parameters such as creatinine clearance and
serum cholesterol level were also within the normal
 .range on day 10 data not shown . These results
confirmed that glucocorticoids are effective in NTS-
nephritis in WKY rats.
Fig. 3. A competition gel shift assay for AP-1 DNA-binding
activity. A gel shift assay with nuclear extracts on day 3 was
 . carried out in the absence lane 1 or presence of AP-1 lanes 2
.  .and 3 and Oct lanes 4 and 5 oligonucleotide competitors; 1 ng
 .  .lanes 2 and 4 and 10 ng lanes 3 and 5 of oligonucleotides were
added, respectively. Similar results were obtained in two inde-
pendent experiments.
3.4. Effects of glucocorticoid on NF-kB and AP-1
acti˝ation
Several lines of evidence indicate that glucocorti-
coids repress NF-k B- and AP-1-dependent transcrip-
tion in cultured cells. However, the molecular mecha-
nisms of glucocorticoid-mediated anti-inflammatory
action in vivo is not well understood. To see whether
glucocorticoid can inhibit the transcription factors in
vivo, we studied the effects of glucocorticoid on the
glomerular NF-k B and AP-1 activation. Gel shift
assays were performed using nuclear extracts pre-
pared from glomeruli after treatment with pred-
nisolone on day 3. As shown in Fig. 5, the NTS-in-
duced increases of both NF-k B and AP-1 DNA-bind-
ing activities were suppressed by prednisolone treat-
ment. These results suggest that glucocorticoids can
suppress NF-k B and AP-1 activation in vivo as well
as in vitro.
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Fig. 4. Preventive effect of glucocorticoid on proteinuria. Pred-
 .nisolone 2 mgrkg was administered orally once a day for
30 min before NTS injection on day 0. On days 3 and 8, urine
samples were collected for 24 h and total protein excretion was
 .  . wdetermined. Each bar shows normal , NTS-treated , NTS
x  .qprednisolone -treated rats, respectively. Data are mean"
S.E. of 5 rats. )P-0.05, ))P-0.01 compared with NTS-treated
 .control Bonferroni’s method .
To determine whether the glucocorticoid-mediated
suppression of NF-k B and AP-1 results in the inhibi-
tion of NF-k B and AP-1 dependent gene expression,
Northern blot analysis was performed by using total
RNAs prepared from glomeruli on day 3 after treat-
ment with prednisolone. Fig. 6 shows that mRNA
expression of IL-1b , MCP-1, ICAM-1 and TGF-b1,
which suggested to be regulated by NF-k B andror
AP-1 in cultured cells, was inhibited by prednisolone
treatment. In contrast, GAPDH mRNA expression
was not affected by prednisolone treatment. These
results suggest that NF-k B and AP-1 might regulate
the induction of pro-inflammatory genes in nephritic
glomeruli in vivo.
3.5. NTS binding and anti-rabbit IgG production
In NTS-nephritis, glomerular injury is triggered by
 .the binding of rabbit anti-GBM antibody NTS in
glomerulus and it might be accelerated by the attack
 .Fig. 5. Preventive effects of glucocorticoid on NF-k B and AP-1 activation. Prednisolone 2 mgrkg was administered before NTS
 .  .injection. Gel shift assays for NF-k B lanes 1–3 and AP-1 lanes 4–6 were carried out using nuclear extracts prepared from glomeruli
 .  . w x  .of normal lanes 1 and 4 , NTS-treated lanes 2 and 5 and NTSqprednisolone -treated lanes 3 and 6 rats on day 3. Representative
data of four rats is shown.
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Fig. 6. Glucocorticoid-mediated inhibition of the target gene
expression for NF-k B and AP-1. Isolated glomeruli from two
animals were collected for the preparation of RNA in each group.
 .Total RNAs were prepared from glomeruli of normal lanes 1 ,
 . w x  .NTS-treated lanes 2 and NTSqprednisolone -treated lanes 3
rats on day 3. Northern blot analysis was performed as described
under Section 2.
of autologous rat anti-rabbit IgG to the rabbit anti-
body on GBM. To demonstrate that these upstream
events are not affected by glucocorticoid treatment,
we investigated the anti-GBM antibody binding to
glomeruli immunohistochemically and measured
serum anti-rabbit IgG level. The anti-GBM antibody
  ..binding to glomeruli on day 1 Fig. 7 A and the
serum anti-rabbit IgG production on day 10 Fig.
 ..7 B were not significantly inhibited by glucocorti-
coid treatment.
3.6. Therapeutic effect of glucocorticoid
In addition to the preventive effects, we examined
the therapeutic effect of glucocorticoid on glomerulo-
nephritis. Prednisolone treatment was started on day
 .3, where moderate proteinuria Fig. 1 and full NF-k B
w x  .31 and AP-1 activation Fig. 2 were observed. Both
the nephritic group and the glucocorticoid-treated
group showed the same level of proteinuria before
the glucocorticoid treatment was started on day 3
  ..Fig. 8 A . In contrast, progression of proteinuria on
days 5 and 7 was suppressed by glucocorticoid treat-
ment as compared to the non-treated nephritic group.
In addition, all animals in the nephritic group showed
hematuria on day 7, which was not observed in the
 .glucocorticoid-treated group data not shown . These
results indicate that glucocorticoids have a therapeu-
tic effect on NTS-nephritis as well as a preventive
effect.
Finally, we investigated the effects of glucocorti-
coid on the already activated NF-k B and AP-1 in
nephritic glomeruli. Significant increases of NF-k B
and AP-1 DNA-binding activities in glomeruli of
  .nephritic animals were detected on day 5 Fig. 8 B ,
.lanes 3 and 4 . In contrast, the NTS-induced in-
creases of both NF-k B and AP-1 DNA-binding activ-
ities were completely suppressed by therapeutic ad-
  .ministration of glucocorticoid from day 3 Fig. 8 B ,
.lanes 5 and 6 . Suppression of NF-k B, but not AP-1,
 .was observed on day 4 data not shown . These
results further support the idea that glucocorticoid-
mediated suppression of NF-k B and AP-1 activation
may be the major components of the anti-nephritic
action of glucocorticoids.
4. Discussion
In this study, we used an experimental NTS-
nephritis model in WKY rats. This strain develops
proliferative and crescentic glomerulonephritis, in re-
sponse to a small amount of NTS compared to other
w xstrains 40 . The susceptibility to NTS might be due
 .to the increased activity of the natural killer NK
w xcells 40 . Kawasaki et al. reported that CD8-positive
 .Fig. 7. Effects of glucocorticoids on NTS binding to glomeruli and serum anti-rabbit IgG production. A Anti-GBM antibody binding to
w xglomeruli was determined by immunohistochemistry on frozen sections prepared from NTS-treated and NTSqprednisolone -treated rats
 .on day 1. Data shows a representative of three animals in each group. B Serum titers of anti-rabbit IgG were determined by ELISA.
w xSera were prepared from normal, NTS-treated and NTSqprednisolone -treated rats on day 10. Data are mean"S.E. of five rats.
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Fig. 8. Therapeutic effects of glucocorticoid on developed
glomerulonephritis and activated NF-k B and AP-1. Daily pred-
 .nisolone treatment 2 mgrkg was started on the third day after
 .NTS injection. A Urinary protein excretion was determined on
 .  .days 0, 3, 5 and 7. Each bar shows normal , NTS-treated ,
w x  .NTSqprednisolone -treated groups, respectively. Data are
mean"S.E. of five rats. ))P -0.01 compared with NTS-treated
 .  .control on day 7 Bonferroni’s method . B the DNA-binding
activities of NF-k B and AP-1 were determined 2 days after
 .prednisolone treatment day 5 . The experiment was carried out
by using two independent rats. The data are obtained from
 .  . wnormal lanes 1 and 2 , NTS-treated lanes 3 and 4 and NTSq
x  .prednisolone -treated lanes 5 and 6 rats. Similar results were
obtained in another experiment.
cells, probably NK cells, infiltrate into glomeruli
w x41 . Depletion of the CD8-positive cells prevented
proteinuria and reduced the severity of histopatholog-
ical changes such as a crescent formation in this
nephritis model. The infiltration of CD8-positive cells
can be detected at least after 4 h until day 11 after
NTS injection and the peak infiltration is observed on
day 3. In addition, macrophage infiltration gradually
increases from 4 h to day 11. NF-k B and AP-1
activation was also detected at this stage, suggesting
a contribution of these cells as a source of NF-k B
and AP-1 activities in nephritic glomeruli. An Oct-2
  ..like protein detected in nephritic glomeruli Fig. 2 B
might be derived from the infiltrated cells because
Oct-2 is known to be expressed preferentially in
w xlymphoid cells 42,43 . Future histochemical analysis
will provide the information on NF-k B and AP-1
expressing cells and pathophysiological significance
of NF-k B and AP-1 activation in glomerulonephritis.
In our previous report, we detected a single NF-
w xk B-derived complex using a gel shift assay 31 . The
complex included the p50 NF-k B subunit which
co-migrated with human recombinant p50 homod-
imer. However, one additional complex was detected
in this study. The detection of this complex depended
on the use of protease inhibitors, aprotinin and leu-
peptin, in buffers for the extraction of glomerular
nuclei. The additional complex was probably derived
from p65rp50 heterodimer, because it migrated
  ..slowly with the p50 homodimer Figs. 5 and 8 B
and reacted with both anti-p65 and anti-p50 antibod-
 .ies data not shown . These results indicate that both
p65rp50 heterodimer and p50rp50 homodimer are
activated during the development of glomerulonephri-
tis.
Several target genes for NF-k B and AP-1 have
been shown to be expressed in glomeruli of NTS-
treated WKY rats. For example, enhanced ICAM-1
expression is detected on day 1 and thereafter and the
w xpeak expression is observed on day 3 8 . Neutraliza-
tion of ICAM-1 by a monoclonal antibody can de-
crease glomerular injury, showed the pathophysiolog-
w xical significance of ICAM-1 8 . In addition, mRNA
expression of other target genes such as IL-1b ,
MCP-1 and TGF-b 1 were induced in nephritic
glomeruli. The kinetics of the expression of target
genes for NF-k B and AP-1 were similar to that of
NF-k B and AP-1 activation. We also showed that
glucocorticoid inhibited IL-1b , MCP-1, ICAM-1 and
 .TGF-b1 mRNA expression Fig. 6 . These results
suggest that the activated NF-k B and AP-1 might
regulate the expression of the pro-inflammatory genes
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in nephritic glomeruli. In contrast to gene expression,
NF-k B and AP-1 activation is shown to precede the
histopathological changes such as mesangial prolifer-
ation and crescent formation, which can be observed
w xon day 6 and thereafter 41 . This evidence suggests
that activation of NF-k B and AP-1 results in
histopathological changes through the transcriptional
induction of genes encoding pathogenic pro-in-
flammatory factors.
We demonstrated that glucocorticoids was able to
suppress NF-k B and AP-1 activation in nephritic
  ..glomeruli in vivo Figs. 5 and 8 B . It is noteworthy
that the suppressive effects were also observed against
NF-k B and AP-1, which were already in the active
  ..state Fig. 8 B . However, mechanisms of the sup-
pression of NF-k B and AP-1 activation are not clear.
Immunohistochemistry showed that glucocorticoids
 .did not interfere with rabbit anti-GBM antibody NTS
  ..binding to glomeruli Fig. 7 A . Autologous anti-
rabbit IgG production is important for the progression
of glomerular injury in NTS-nephritis. Unexpectedly,
the autologous antibody production on day 10 was
not affected by glucocorticoids at the effective dose
  ..to suppress proteinuria Fig. 7 B . In addition, sup-
pression of NF-k B and AP-1 by glucocorticoids was
 .detected on day 3 and 5 Figs. 5 and 8 , where the
serum anti-rabbit IgG was not increased data not
.shown . These results suggest that glucocorticoids
might suppress glomerulonephritis by inhibiting acti-
vation of NF-k B and AP-1 selectively, but not
through the systemic immunosuppression.
In summary, we have demonstrated that NF-k B
and AP-1 are activated in nephritic glomeruli and that
NF-k B and AP-1 may have a regulatory role in the
expression of pro-inflammatory factors in nephritic
glomeruli. In vivo suppression of NF-k B and AP-1
activation by glucocorticoids in nephritic glomeruli
may be one mechanism by which glucocorticoids
suppress glomerulonephritis. These findings also pro-
vide a novel molecular approach for treatment of
glomerulonephritis by selectively controlling NF-k B
and AP-1 activities.
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